Last reviewed · How we verify
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected solid tumors whose disease is locally advanced, recurrent, or metastatic and for whom an investigational agent in combination with an anti-PD-L1 antibody is considered an acceptable treatment option.
Details
| Lead sponsor | Hoffmann-La Roche |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 64 |
| Start date | Thu May 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- PD-L1-selected Solid Tumors
Interventions
- Tiragolumab and Atezolizumab IV FDC
Countries
Greece, Serbia, Taiwan, South Korea, China, Croatia, United States, Turkey (Türkiye), Spain